Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Subtype terms (5)
More specific conditions that are subtypes of Melanoma in the MeSH hierarchy.
- Cutaneous Malignant Melanoma
- Hutchinson's Melanotic Freckle
4 drugs approved
- Melanoma, Amelanotic
- Melanoma, Experimental
5 drugs (3 approved, 2 experimental)
- Uveal Melanoma
Drugs by status
Approved for this indication (21)
Phase 4 trials (19)
Phase 3 trials (112)
- cemiplimab
- bempegaldesleukin
- mgc018
- sorafenib
- mart-1 peptide pulsed dendritic cells
- spartalizumab
- sintilimab
- Zastumotide
- temozolomide
- gm2-klh vaccine
- hyaluronidase (human recombinant)
- ide196
- pol-103a
- mdx-1379
- dendritic cells
- paclitaxel
- montanide isa51
- tasisulam
- propranolol
- melanoma vaccine modified to express hla a2/4-1bb ligand
- tumor necrosis factor
- belzupacap sarotalocan
- rose bengal
- aflibercept
- na17.a2 peptide
- csf470
- melatonin
- vitamin d3
- human serum albumin/interferon alpha2b fusion protein
- acetaminophen
- +82 more
Phase 2 trials (669)
- trastuzumab emtansine
- sarilumab
- gc101 til
- atl001
- mydc
- metformin
- hf10
- ilb2109
- mage-3/melan-a/gp100/na17 pbmc, rhil-12
- gen1046
- env-501
- veledimex
- mage-3/melan-a/gp100/na pbmc
- dovitinib
- aluminum
- dendritic cells - transfected with htert-, survivin- and tumor cell derived mrna + ex vivo t cell expansion and reinfusion
- candida albicans allergen
- Gebasaxturev
- dcb-bo1301
- interleukin-12
- apg-115
- nc318
- cm-24
- anti-ny eso-1 mtcr pbl
- fludeoxyglucose f-18
- ibuprofen
- mrna coding for melanoma associated antigens
- Anti-thymocyte Globulin (Rabbit)
- mage-a3 asci
- nogapendekin alfa inbakicept
- +639 more
Phase 1 trials (442)
- hfb200301
- dky709
- pf-07329640
- neo-ptc-01
- mage-10.a2
- bat4706
- ngm438
- nx-1607
- enoblituzumab
- sgn-cd47m
- Afamitresgene autoleucel
- pnt6555
- certolizumab pegol
- sasanlimab
- keyhole limpet hemocyanin
- autologous total tumor mrna loaded dotap liposome vaccine
- pf-07799933
- grn-1201
- 70-kd heat-shock protein
- lvgn6051
- sgn-pdl1v
- mem-288
- furosemide
- mln-1202
- ski-249380
- langerhans-type dendritic cells
- crx100
- ab821
- autologous cytokines
- atrc-101
- +412 more
Other trials (38)
- technetium tc 99 hydrazinonicotinamide-tricine-linked interleukin-2
- fruquintinib
- gx-i7
- ketone
- il-12 dna
- glucose
- gag:267-274 peptide vaccine
- lidocaine
- high-selenium yeast
- gd3l
- gla-se
- chlorhexidine
- ringer's lactate
- urolithin a
- pbr
- 18f-peg3-fpn
- voriconazole
- parthenolide
- autologous human tumor-derived hsppc-96
- autologous tumor cells
- chicory root
- 89zr-pembrolizumab
- methylene blue
- gd2l
- cd19 car-t cells
- citicoline
- agen2034
- fluorescein
- anti-cd19/20-car vector-transduced t cells
- nicotine
- +8 more
Organizations
Organization Involved with Phase 4 Indications (23)
- University of Barcelona
- Medical Center Buxtehude
- Humboldt University
- Prometheus Inc.
- University of Lyon
- Dermatologic Cooperative Oncology Group
- Amgen
- Shields, Shields and Associates
- University of Alabama, Birmingham
- Melanoma Institute Australia
- University of Texas at Houston
- Novartis
- University of Oxford
- Thomas Jefferson University
- Otto von Guericke University
- Baxalta
- Mayo Clinic
- Osaka University
- Aix-University of Marseille
- Johns Hopkins University
- National Health Service, United Kingdom
- University of Pennsylvania
- University of Kiel
Organization Involved with Phase 3 Indications (117)
- University of Glasgow
- Polynoma LLC
- Emory University
- TC Biopharm
- Indiana University
- Baylor University
- NewLink Genetics Inc
- Innovent Biologics (Suzhou) Co. Ltd.
- Oregon Health and Science University
- University of Washington
- ECOG-ACRIN Cancer Research Group
- Agenus Inc.
- University of Nantes
- Katholieke Universiteit Leuven
- Nektar Therapeutics
- Caladrius Biosciences
- Icahn School of Medicine at Mount Sinai
- Saarland University
- Medarex
- European Organisation for Research and Treatment of Cancer
- Medac
- Leiden University
- University of Alberta
- ZonMw: The Netherlands Organisation for Health Research and Development
- Philogen S.p.A.
- Fondazione Giovanni Pascale
- University of Tuebingen
- DCS Innovative Diagnostik Systeme
- Provectus Biopharmaceuticals, Inc.
- University of Erlangen-Nuremberg
- +87 more
Organization Involved with Phase 2 Indications (380)
- Cadila Healthcare
- ICO Hospital Durans i Reynals
- University of Rochester
- Hoag Memorial Hospital Presbyterian
- Takara Bio Inc.
- University of Michigan
- Medivation
- National Cancer Institute, France
- American Society of Clinical Oncology
- Aqualis
- Allergan
- Cancer Treatment Centers of America
- The Jewish General Hospital, Montreal QC, Canada
- Keio University
- Moorgreen Hospital, Southampton
- St. Jude Children's Hospital
- Introgen Therapeutics
- Shenzhen Hank Bioengineering Institute
- Midwest Melanoma Partnership
- Intergruppo Melanoma Italiano
- Oncology Service, Wills Eye Institute
- Yonsei University
- BioNumerik Pharmaceuticals, Inc.
- PDL BioPharma
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Academic and Community Cancer Research United
- The First People's Hospital of Changzhou
- Biothera
- NovoCure Ltd.
- Mirna Therapeutics
- +350 more
Organization Involved with Phase 1 Indications (120)
- University of Buenos Aires
- Celerion
- Sierra Oncology, Inc.
- Cytosite Biopharma Inc.
- Food and Drug Administration
- University of South Carolina
- University of Oklahoma
- Zai Lab Pty. Ltd.
- InxMed (Shanghai) Co., Ltd.
- Vaccinex Inc.
- Mundipharma
- DLR German Aerospace Center
- AO GENERIUM
- Millennium Pharmaceuticals
- Imclone
- ZymoGenetics
- United States Army
- Xencor
- Medical University of Vienna
- Maastricht University
- CHU AMBROISE PARE
- Xynomic Pharmaceuticals, Inc.
- University of Queensland
- Advanced Life Sciences
- University of Massachusetts
- Austin Health
- Varian Medical Systems
- University of Rome Tor Vergata
- National Human Genome Research Institute (NHGRI)
- Neon Therapeutics
- +90 more
Organization Involved with Other Experimental Indications (12)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Center Trials & Treatment Inc.
- People's Liberation Army of China
- Karsh Family Research Fund
- Sky Ridge Medical Center
- Centro de Investigación en Nanomateriales y Nanotecnología (CINN)
- DENSMORE pharmaceuticals
- Government of Taiwan
- Barretos Cancer Hospital
- Martin Luther University
- OHSU Knight Cancer Institute
- Morristown Memorial Hospital